Once-daily mometasone furoate nasal spray: Efficacy and safety of a new intranasal glucocorticoid for allergic rhinitis

Clinical Therapeutics

Volumn 19, Issue 1, 1997, Pages 27-38

  Davies, Robert J ^a   Nelson, Harold S ^b  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

intranasal glucocorticoids; mometasone furoate nasal spray; perennial rhinitis; seasonal allergic rhinitis

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; FLUTICASONE PROPIONATE; GLUCOCORTICOID; MOMETASONE FUROATE; NOSE SPRAY; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; HEADACHE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INTRANASAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; META ANALYSIS; NONHUMAN; NOSE IRRITATION; NOSE MUCOSA; PATIENT COMPLIANCE; PERENNIAL RHINITIS; REVIEW; SEASONAL VARIATION;

EID: 0030901541     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80070-7     Document Type: Article

References (24)

1. Mygind N. Glucocorticoids and rhinitis. Allergy. 1993;4:476-490.
2. Meltzer EO. Today's approach to controlling allergic rhinitis. J Respir Dis. 1992;13 (Suppl 6):S30-S39.
3. Naclerio RM. Allergic rhinitis. NEJM. 1991;325:860-869.
4. Mabry RL. Glucocorticoids in the management of upper respiratory allergy: The emerging role of steroid nasal sprays. Otolaryngol Head Neck Surg. 1992;107: 855-860.
5. Mabry RL. Glucocorticoids in otolaryngology: Nasal aerosols. Otolaryngol Head Neck Surg. 1989;100:636-637.
6. Rosenthal D, Duke E. A clinical investigation of the efficacy and safety of mometasone furoate ointment 0.1% versus betamethasone valerate ointment 0.1% in the treatment of psoriasis. Curr Ther Res. 1988;44:790-801.
7. Bressinck R, Williams J, Peets E. Comparison of the effect of mometasone furoate ointment 0.1%, and hydrocortisone ointment 1.0%, on adrenocortical function in psoriasis patients. Today's Ther Trends. 1988;5:25-34.
8. Medansky RS, Bressinck R, Cole GW. Mometasone furoate ointment and cream 0.1 percent in treatment of psoriasis: Comparison with ointment and cream formulations of fluocinolone acetonide 0.025 percent and triamcinolone acetonide 0.1 percent. Cutis. 1988;42:480-485.
9. Barton BE, Jakway JP, Smith SR, Siegel MI. Cytokine inhibition by a novel steroid, mometasone furoate. Immunopharmacol Immunotoxicol. 1991;13:251-261.
10. Umland SP, Narhebne DK, Razac BS, et al. Effects of mometasone furoate and other glucocorticoids on cytokine production from cultured peripheral blood CD4+ T cells. J Allergy Clin Immunol. 1996;97: 288. Abstract.
11. Therattil J, Chavarria V, Cosachov J, et al. The effect of mometasone furoate on early and late phase inflammation in patients with seasonal allergic rhinitis (SAR). Ann Allergy Asthma Immunol. 1997;78:129. Abstract.
12. Bronsky EA, Pedinoff A, Nolop K. Dose ranging study of the activity and tolerance of mometasone furoate in seasonal allergic rhinitis. Allergy. 1996;50:191-192. Abstract.
13. Berkowitz RB, Nolop RB, Mesarina-Wicki BE, and the C93-184 Study Group. Onset of action of mometasone furoate (Nasonex) nasal spray in seasonal allergic rhinitis. J Allergy Clin Immunol. 1997;99 (Part 2):S441. Abstract.
14. Hebert JR, Nolop K, Lutsky B. Once daily mometasone furoate aqueous nasal spray (Nasonex) in seasonal allergic rhinitis: An active- and placebo-controlled study. Allergy. 1996;51:569-576.
15. Graft D, Aaronson D, Chervinsky P, et al. A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray. J Allergy Clin Immunol. 1996;98:724-731.
16. Marazzi P, Nolop K, Lutsky BN, and the 193-133 Study Group. Prophylactic use of once-daily mometasone furoate (Nasonex) aqueous nasal spray in patients with seasonal allergic rhinitis. J Allergy Clin Immunol. 1997;99(Part 2):S440. Abstract.
17. Drouin M, Yang WH, Bertrand B, et al. Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for perennial allergic rhinitis patients. Ann Allergy Asthma Immunol. 1996;77:153-160.
18. Day J, Nolop K, Lutsky BN. Comparison of once-daily treatment with mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. J Allergy Clin Immunol. 1997;99(Part 2):S441. Abstract.
19. Nasonex®. Schering-Plough Inc., Kenilworth, New Jersey. Product Information.
20. Brannan MD, Seiberling M, Cutler DL, et al. Lack of systemic activity with intranasal mometasone furoate. J Allergy Clin Immunol. 1996;97:198. Abstract.
21. Brannan MD, Herron JM, Reidenberg P, et al. Lack of HPA axis suppression following 36 days of intranasal mometasone furoate. Ann Allergy Asthma Immunol. 1997;78:154. Abstract.
22. Data on file, Schering-Plough Research Institute, Schering-Plough Inc., Kenilworth, NJ, 1996.
23. O'Brien F, Minshall E, Nolop K, et al. Histological and immunocytochemical assessment by nasal biopsy of mometasone furoate nasal spray in perennial rhinitis. J Allergy Clin Immunol. 1997;99(Part 2): S498. Abstract.
24. Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel technique. JAMA. 1989; 261:3273-3277.